• Product name

    Anti-CILP antibody [EPR16303]
    See all CILP primary antibodies
  • Description

    Rabbit monoclonal [EPR16303] to CILP
  • Host species

  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human CILP aa 1-100. The exact sequence is proprietary.
    Database link: O75339

  • Positive control

    • Human cartilage lysate
  • General notes



    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab192881 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 90 kDa (predicted molecular weight: 133 kDa).


  • Function

    Probably plays a role in cartilage scaffolding. May act by antagonizing TGF-beta1 (TGFB1) and IGF1 functions. Has the ability to suppress IGF1-induced proliferation and sulfated proteoglycan synthesis, and inhibits ligand-induced IGF1R autophosphorylation. May inhibit TGFB1-mediated induction of cartilage matrix genes via its interaction with TGFB1. Overexpression may lead to impair chondrocyte growth and matrix repair and indirectly promote inorganic pyrophosphate (PPi) supersaturation in aging and osteoarthritis cartilage.
  • Tissue specificity

    Specifically expressed in cartilage. Localizes in the intermediates layer of articular cartilage but neither in the superficial nor in the deepest regions. Specifically and highly expressed in intervertebral disk tissue. Expression increases with aging in hip articular cartilage. Overexpressed in articular hyaline cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease (CPPD). Expression in intervertebral disk tissue from individuals with lumbar disk disease increases as disk degeneration progresses.
  • Involvement in disease

    Defects in CILP are a cause of susceptibility to intervertebral disk disease (IDD) [MIM:603932]. A common musculo-skeletal disorder caused by degeneration of intervertebral disks of the lumbar spine. It results in low-back pain and unilateral leg pain. Note=Susceptibility to intervertebral disk disease, is conferred by variant p.Ile395Thr (PubMed:15864306).
  • Sequence similarities

    Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
    Contains 1 TSP type-1 domain.
  • Post-translational

    Cleaved into 2 chains possibly by a furin-like protease upon or preceding secretion.
  • Cellular localization

    Secreted > extracellular space > extracellular matrix.
  • Information by UniProt
  • Database links

  • Alternative names

    • Cartilage intermediate layer protein 1 antibody
    • Cartilage intermediate layer protein 1 C1 antibody
    • Cartilage intermediate layer protein 1 C2 antibody
    • cartilage intermediate layer protein antibody
    • cartilage intermediate layer protein, nucleotide pyrophosphohydrolase antibody
    • Cartilage intermediate-layer protein antibody
    • CILP 1 antibody
    • CILP antibody
    • CILP-1 antibody
    • CILP1_HUMAN antibody
    • HGNC:1980 antibody
    • HsT18872 antibody
    see all


  • Anti-CILP antibody [EPR16303] (ab192881) at 1/5000 dilution + Human cartilage lysate at 10 µg

    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size: 133 kDa
    Observed band size: 90 kDa
    why is the actual band size different from the predicted?


ab192881 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab192881.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up